For years, health care professional (HCP) engagement has rested on a flawed assumption: that more information, delivered ...
Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and ...
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits ...
Under terms of the agreement, IntraBio is expected to become a wholly owned subsidiary of Shionogi Inc., Shionogi's New Jersey-based subsidiary. 1 Shionogi Inc. will also acquire all outstanding ...
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects ...
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible. Real-world data (RWD) is an essential resource for finding insights ...
Along with rising sales, GLP-1s are a major focus for R&D teams. Major pharma companies are developing new versions of the ...
When people feel dismissed, confused or misaligned with their healthcare experience, they often quietly disengage long before ...
CSL will pay $355M upfront to Alentis plus up to $1.2B milestones, while financing Phase II completion and Phase III in AAV-RPGN and Phase II programs in FSGS and PSC. Lixudebart targets claudin-1, ...
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...
Termination of the SMARCA2 program reflects insufficient antitumor activity despite acceptable tolerability, highlighting the gap between mechanistic rationale and clinical benefit in synthetic lethal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results